July 2024 HCPCS Updates

CMS has released the July 2024 Healthcare Common Procedure Coding System (HCPCS) file. Inclusion on this list does not indicate coverage. All HCPCS code changes are effective and should be used for claims with dates of service on or after July 1, 2024. Watch the Noridian website for additional policy updates regarding these HCPCS codes.

Added HCPCS Codes

Effective for dates of service on and after July 1, 2024

HCPCS DESCRIPTION
J0211 Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
J0872 Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
J1597 Injection, glycopyrrolate (glyrx-pf), 0.1 mg
J1598 Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
J1748 Injection, infliximab-dyyb (zymfentra), 10 mg
J2183 Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg
J2246 Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
J2267 Injection, mirikizumab-mrkz, 1 mg
J2373 Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
J2470 Injection, pantoprazole sodium, 40 mg
J2471 Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg
J3247 Injection, secukinumab, intravenous, 1 mg
J3263 Injection, toripalimab-tpzi, 1 mg
J3393 Injection, betibeglogene autotemcel, per treatment
J3394 Injection, lovotibeglogene autotemcel, per treatment
J8611 Methotrexate (jylamvo), oral, 2.5 mg
J8612 Methotrexate (xatmep), oral, 2.5 mg
J9361 Injection, efbemalenograstim alfa-vuxw, 0.5 mg
Q5137 Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
Q5138 Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg

Description Update

The long description of the HCPCS code has been updated as of July 1, 2024

HCPCS DESCRIPTION
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg
J0173 Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg
J0401 Injection, aripiprazole (abilify maintena), 1 mg
J0651 Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg
J0652 Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg
J0873 Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
J0893 Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J1574 Injection, ganciclovir sodium (exela), not therapeutically equivalent to j1570, 500 mg
J1806 Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg
J1921 Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
J2021 Injection, linezolid (hospira), not therapeutically equivalent to j2020, 200 mg
J2184 Injection, meropenem (b braun), not therapeutically equivalent to j2185, 100 mg
J2251 Injection, midazolam hydrochloride (wg critical care), not therapeutically equivalent to j2250, per 1 mg
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg
J2281 Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
J2599 Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit
J2806 Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms
J3244 Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mg
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg
J3372 Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
J9046 Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg
J9172 Injection, docetaxel (ingenus), not therapeutically equivalent to j9171, 1 mg
J9258 Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
J9259 Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
J9294 Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg
J9296 Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg
J9314 Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
J9322 Injection, pemetrexed (blue point), not therapeutically equivalent to j9305, 10 mg
J9393 Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Deleted HCPCS Code

Invalid for billing for dates of service July 1, 2024 and after

HCPCS DESCRIPTION
J2780 Injection, Ranitidine Hydrochloride, 25 MG
J9371 Injection, Vincristine Sulfate Liposome, 1 MG
Last Updated Jun 07 , 2024